Nattokinase for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Nattokinase for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

Nattokinase is a clot-dissolving enzyme from fermented soybeans. The strongest evidence is a modest blood-pressure drop in people who already run high. Changes in clotting proteins after a dose are real. Plaque shrinkage claims are not backed by the longest independent trial. Product quality is uneven. Not a substitute for prescription blood thinners or proven blood-pressure medicines. (Full Review)

Protocol

Research-dose protocol (Kim, Jensen, Hodis, EFSA NSK-SD)
2,000 FU once daily
About 100 mg of a vitamin K2–removed extract; typically 8 weeks before judging blood pressure
Time of day
Empty stomach
Often morning; food competition is the practical constraint
High-dose observational protocol (Ren, Chen/Sungen)
6,000–10,800 FU/day
Aimed at carotid plaque; not independently replicated in a long randomized trial
Time to effect
Blood pressure
8 weeks
Replicated in people who start high; 3-year healthy-adult trial was null
Fibrinolytic labs
2–8 hours
After a dose; marker shifts last about 8 hours
Plaque imaging
6–12 months
High-dose claims; no 3-year structural gain at 2,000 FU

Benefits

Contraindications
  • Active or recent bleeding, peptic ulcer, or known coagulation disorder
  • Recent ischemic stroke, cerebral microbleeds, or bleeding-prone small-vessel brain disease
  • Mechanical prosthetic heart valve or other condition that requires therapeutic anticoagulation
  • Vitamin K antagonists (warfarin) as replacement
  • Planned surgery or dental extraction (stop at least 2 weeks prior)
  • Pregnancy and lactation (no adequate safety data)
  • Known soy, natto, PGA, or nattokinase (Bac s 1) allergy
    •
Key Interactions
  • Vitamin K antagonists (warfarin): caution as add-on
  • Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban)
  • Antiplatelets (aspirin, clopidogrel, ticagrelor)
  • Heparins and fondaparinux (enoxaparin, unfractionated heparin)
  • Antihypertensives (ACE inhibitors such as lisinopril; ARBs such as losartan; calcium-channel blockers such as amlodipine)
  • NSAIDs (ibuprofen, naproxen) and high-dose fish oil, garlic, ginkgo, or vitamin E
  • Red yeast rice / monacolin K (lovastatin-like) products
  • Serrapeptase, lumbrokinase, and other fibrinolytic enzymes
    •

Risk & Side Effects

  • High:
  • Medium: Prolonged clotting times and lower clotting-factor levels
  • Medium: Small rise in blood glucose
    •
  • Low: Intracerebral hemorrhage when combined with antiplatelet therapy
  • Low: Allergic reactions, including anaphylaxis to natto components
  • Low: Valve thrombosis after replacing warfarin
  • Low: Histamine intolerance in diamine oxidase deficiency
    •
  • Speculative:

Monitoring

Marker Target Why
Systolic/diastolic BP 110–120 / 70–80 mmHg Most replicated human effect
Fibrinogen 200–300 mg/dL Enzyme’s clotting-protein target
D-dimer At/below local cutoff; track vs own baseline Marks fibrin breakdown
aPTT and PT/INR Unchanged from own baseline; INR in the prescribed band if on warfarin Additive anticoagulant effect
LDL-C (or apoB) Often <70–100 mg/dL in prevention settings Lipids may worsen at 2,000 FU
Fasting glucose 70–85 mg/dL (conventional <100) Meta-analysis glucose signal
Hemoglobin / CBC Stable vs own baseline Occult bleed screen
Carotid IMT/plaque No universal target; change vs own baseline Only if plaque is the stated goal

Cadence: Baseline (home blood pressure morning and evening for a week, plus labs). Repeat labs at 8 weeks, then every 3–6 months if use continues. Imaging, if used, at 6–12 months, not at week 8.

Qualitative Assessment

  • New bruising, nosebleeds, bleeding gums, or unusually heavy menses
  • Lightheadedness on standing (blood-pressure overshoot)
  • Allergic flushing, delayed hives, or wheeze after natto-containing products
  • No expected blood-pressure change by 8 weeks at a verified-FU dose
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.